1.	Drug-eluting Bead in Hepatocellular Carcinoma Phase: Phase IV Type: Treatment Status: Enrolling by invitation Age: 20 and over Sponsor: Other Protocol IDs: Biocompatible-Korea, NCT01332669
2.	Trial of Myocet in Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 an over Sponsor: Pharmaceutical / Industry Protocol IDs: STM01-102, NCT00294996
3.	Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: C19562/2037/BC/EU, EudraCT number: 2008-000709-12, NCT00712881
4.	Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: GOG/2007-01, 2007-005173-56, NCT00721747
5.	A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDX011-03, NCT01156753